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Effects of dehydroepiandrosterone and quinapril on nephropa- The obese Zucker rat exhibits insulin resistance, hy-
thy in obese Zucker rats. perinsulinemia, and hyperlipidemia [1, 2]. Because it
Background. The obese Zucker rat exhibits insulin resistance, shares many common characteristics with human type 2
develops nephropathy at an early age, and may be a model of diabetes mellitus [3] and spontaneously develops kidney
diabetic nephropathy. Dehydroepiandrosterone (DHEA) may
damage, some investigators consider it to be an animalameliorate many of the factors that contribute to diabetic ne-
model of diabetic nephropathy [4–7]. These rats developphropathy, while angiotensin-converting enzyme inhibitors are
glomerular hypertrophy with mesangial expansion by 3known to be effective. One marker of nephropathy is the ex-
months of age [8], express albuminuria around 14 weekspression of a-smooth muscle actin.
Methods. We studied the effect of DHEA on the expression [4], and begin exhibiting glomerulosclerosis by 28 weeks
of a-smooth muscle actin in obese Zucker rats and compared [4]. The hyperlipidemia exhibited by obese Zucker rats
the changes with those in a control group, a group given quin- may be responsible for at least some of their nephropathy
april, and a group on a low-calorie diet. DHEA (0.6%) added [9, 10], and a reduction of hyperlipidemia is beneficial,
to plain chow, quinapril (0.3 mg/kg) added to drinking water, whether by diet alone or with pharmacological interven-and a low-calorie diet based on pair-feeding were administered
tion [11–14].to obese rats from age 4 to 20 weeks. Immunohistochemical
Macrophages are the first inflammatory cells foundexpression of a-smooth muscle actin, a marker of interstitial
in the glomeruli of obese Zucker rats, and their influxand glomerular fibrosis and an early indicator of nephropathy,
was measured semiquantitatively in glomeruli, cortical intersti- precedes both mesangial expansion and thickening of
tium, and medullary interstitium on a scale of 0 to 4 and was the glomerular basement membrane [8]. Their presence
reported as mean 6 SEM. coincides with the occurrence of cortical interstitial in-
Results. When compared with the obese control group, quin- jury and precedes medullary interstitial injury [15]. Their
april exhibited a marked reduction in a-smooth muscle actin recruitment and activation within the glomerulus play a
staining in glomeruli, cortical interstitium, and medullary inter-
vital role in the development and progression of ne-stitium (P , 0.0005); DHEA reduced a-smooth muscle actin
phropathy [16]. The tubulointerstitial lesions of Zuckerstaining in cortical interstitium and medullary interstitium (P ,
rats demonstrate a focal concentration of predominantly0.005), and a low-calorie diet reduced a-smooth muscle actin
monocyte/macrophages [10]. Nonresident macrophagesstaining in cortical and medullary interstitium (P , 0.005),
which was similar to the effects of DHEA. are found throughout the kidney [16, 17], and interven-
Conclusions. DHEA was similar to a low-calorie diet in tions that limit their activation may also slow the progres-
reducing the immunohistochemical staining of a-smooth mus- sion of diabetic nephropathy. The effect of such interven-
cle actin in obese Zucker rats. However, quinapril exerted a tions can be assessed with 24-hour urine protein and
marked protective effect on the development of fibrosis, as
renal fibrosis. One of the hallmarks of diabetic nephropa-indicated by a-smooth muscle actin staining, which was signifi-
thy is the fibrosis that occurs in both the glomeruluscantly less than that of DHEA at the doses studied.
and the tubulointerstitium [18]. One early indicator of
fibrosis is the expression of a-smooth muscle actin [19]
by renal vascular and visceral smooth muscle cells andKey words: a-smooth muscle actin, proteinuria, albuminuria, fibrosis,
hyperinsulinemia, type 2 diabetes mellitus. activated mesangial cells [20].
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Zucker rat [22]. These drugs inhibit the immunohisto- individual metabolic cage for urine collections while con-
tinuing to have ad libitum access to their food and water.chemical expression of a-smooth muscle actin in both
the glomerulus [23] and the interstitium [24]. However, After a 72-hour acclimation period, a 24-hour urine col-
lection was obtained, and the animals returned to theirother drugs, for example, those directed against macro-
phages, may also be beneficial. Macrophages produce a usual cages.
Another group of male obese rats (N 5 6) was alsonumber of cytokines and have been implicated in the
development and progression of diabetic nephropathy randomly chosen from the colony at four weeks of age
and was handled in the same manner as described pre-[16]. One agent that may ameliorate the production of
certain cytokines by the macrophage is the steroid hor- viously in this article with the exception of their diet.
Briefly, these animals were pair fed with an amount ofmone dehydroepiandrosterone (DHEA) [25]. DHEA
has been shown to inhibit the age-related development powdered rat chow that matched the weekly historical
mean amount of food consumed by the DHEA-treatedof proteinuria in mice and Sprague-Dawley rats [26], but
there are no published reports of the effect of DHEA obese rats. (They were given neither DHEA nor quin-
april.)specifically on the obese Zucker rat model of diabetic
nephropathy. Because of the role of macrophages in Within a few days of reaching 20 weeks of age (mean
2.7 days, range 1 to 7 days), the animals were fasted fornephropathy and the potential effect of DHEA on these
macrophages, we postulated that DHEA administration 12 to 18 hours and were sacrificed by rapid decapitation.
Blood was collected on ice and centrifuged under re-would slow the progression of diabetic nephropathy. In
this study, we compare the renal effects of DHEA to frigeration to obtain serum, which was stored at 2708C.
The kidneys were removed and weighed. Longitudinalthe effects of the ACE inhibitor quinapril, a known bene-
ficial agent in diabetic nephropathy. sections were fixed in zinc formalin. After being embed-
ded in paraffin, 2 mm sections were mounted on poly-l-
lysine–coated slides (Polysciences, Inc., Warrington, PA,
METHODS
USA). Immunohistochemical staining was done with a
Zucker rats were obtained from the breeding colony monoclonal anti–a-smooth muscle actin antibody (clone
maintained at the Louisiana State University Medical #1A4, lot #107F-4806; Sigma Chemical) and was counter-
Center (New Orleans, LA, USA) by the Department of stained with hematoxylin. A renal pathologist, blinded
Physiology and were kept in a temperature and humidity to the phenotype and treatment of each animal, reviewed
controlled environment with a daily 12-hour light and 20 consecutive cortical glomeruli under 3400 magnifica-
12-hour dark schedule. Heterozygous (fa/1) lean (N 5 tion; 10 random areas of cortical periglomerular intersti-
21) and homozygous (fa/fa) obese (N 5 16) male Zucker tium under 3400 magnification, each area approximately
rats were randomly chosen at four weeks of age when 25,000 mm2 and five random areas of medullary intersti-
they could be weaned safely from their mother. The tium under 3400 magnification, each area approximately
animals were fed either powdered laboratory rodent 12,000 mm2. The extent of a-smooth muscle actin staining
chow #5001 (Purina Mills, Inc., St. Louis, MO, USA) and was determined with a 100-point ocular integrator plate.
served as controls or were fed powdered chow containing Each glomerulus or area of interstitium was assigned a
DHEA (Sigma Chemical Co., St. Louis, MO, USA) at semiquantitative score of 0 to 4 [0, normal; 1, isolated
a concentration of 6 g/kg of chow (0.6% by weight). (,25%); 2, minimal and focal (25 to 50%); 3, moderate
Most investigators administering DHEA to rats use ei- and diffuse (51 to 75%); 4, severe, generalized, and con-
ther 0.3% or 0.6% of DHEA. Since the effects of DHEA fluent (.75%)] reflecting the extent of a-smooth muscle
are dose dependent [27], 0.6% was chosen for this proto- actin present. This technique shows a high correlation
col. The ACE inhibitor chosen for this protocol was with classic morphometric analysis [30].
quinapril because of its high degree of tissue ACE inhibi- Serum assays for creatinine, total protein, albumin,
tion at low doses [28, 29]. Quinapril (supplied by Parke- and sodium as well as urine assays for creatinine, total
Davis Pharmaceuticals, Ann Arbor, MI, USA) was added protein, and sodium were performed by standard auto-
to the drinking water of additional (N 5 12) male obese mated laboratory techniques using the Paramax 720ZX
Zucker rats, six of which were fed plain chow and the Automated Chemistry Analyzer (Baxter Healthcare Corp.,
remaining six fed chow containing DHEA as described Paramax Systems Division, Irvine, CA, USA). Urine albu-
previously in this article. Water consumption was moni- min was measured with a commercially available enzyme-
tored, and the concentration of quinapril in the drinking linked immunosorbent assay (ELISA) kit specific for rat
water was adjusted weekly with the intended 24-hour urine albumin (Nephrat kit; Exocell, Inc., Philadelphia,
drug administration goal of 0.3 mg/kg. All of these rats PA, USA). Glomerular filtration rate (GFR) was deter-
were housed individually in group-sized, hanging wire- mined from the 24-hour urine collection.
mesh cages and had unlimited access to food and water. All animals were treated humanely under the guide-
lines of the National Institutes of Health and the AnimalAt 16 and 20 weeks of age, each rat was placed in an
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Fig. 1. Urinary albumin excretion of each animal by group along with group means and SEM. Symbols are: (s) each individual animal; (d) with
error bars represent the mean and SEM of each group. Statistical differences between groups are reported in Table 2. Statistical differences
between week 16 and week 20 albuminuria within each group were determined by paired t test and are listed beneath each graph.
Welfare Act. The protocol for this experiment was ap- degree similar to that from DHEA alone. Caloric restric-
tion in the pair-fed group reduced kidney size to theproved by the Louisiana State University Medical Center
Institutional Animal Care and Use Committee (IACUC). same degree as that from DHEA alone or with quinapril.
The kidney weights are also expressed as a percentageAll results are listed as mean 6 SEM where appro-
priate. Results were analyzed by two-way analysis of of total body weight.
variance with JMP version 3.1.6.2 statistical software
Creatinine(SAS Corp., Cary, NC, USA). Differences between
groups were determined using the “Fit Model” routine The lean and obese rats generally had a similar serum
creatinine (Table 1). However, treatment with DHEA,with phenotype, diet, and phenotype 3 diet as indepen-
dent variables which uses the Tukey-Kramer HSD post either alone or in combination with quinapril, reduced
creatinine levels.hoc test. A P value ,0.05 was considered significant.
The P values listed on Figure 1 were obtained with the
Urine volumepaired t-test analysis of week 16 and week 20 albumin-
uria. The lean rats given DHEA exhibited less urine volume
(Table 2) than lean controls at 16 and 20 weeks of age.
DHEA administration to obese rats reduced urine vol-
RESULTS
ume at 20 weeks, but not at 16 weeks. Quinapril treat-
Kidney weight ment alone increased urine volumes, but there was no
change when quinapril was given in combination withAs reported in Table 1, DHEA administration to the
lean rats resulted in smaller kidneys. The obese controls DHEA. Pair feeding had minimal effects on urine
volume.had larger kidneys than the lean controls, and the obese
rats given DHEA had smaller kidneys than the obese
Urine protein excretioncontrols. Quinapril treatment resulted in smaller kid-
neys, but not as small as with DHEA. The addition of Proteinuria at 16 weeks was only reduced in the pair-
feeding group (Table 2). At 20 weeks, proteinuria wasDHEA to quinapril reduced kidney size further to a
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Table 1. Body weight, food intake, total cholesterol, kidney weight, serum creatinine, glomerular filtration rate (GFR),
fractional excretion of sodium (FENa), and a-smooth muscle actin staining
Lean Lean Obese Obese Obese Obese DHEA Obese
controls DHEA Controls DHEA quinapril and quinapril pair fed
N 10 10 8 8 6 6 6
Body weightf g 343.0611.3a,e 206.766.6b 486.5615.1c 316.5617.1a 451.8620.3d 341.8613.4a 378.168.4e
Total food intakef kCal 75246115a 56416118b 89446238c 69056423a,d 75006316a 66056323d 6723660d
Total cholesterolf mg/dL 78.363.1a 74.261.8a 146.8614.1b 99.165.4c 105.264.9c 103.766.8c 106.8611.7c
Total kidney weight g 2.41460.057a 1.67060.072b 2.76260.125c 2.10160.089d 2.43960.128a 2.02860.085d 2.03260.064d
Total kidney weight % of
body weight 0.7060.01a,x 0.7960.01b 0.5760.01c 0.6760.02a 0.5960.06c,d 0.6460.01a,d,x 0.5460.01c
Creatinine mg/dL 0.3260.02a,x 0.2760.02a,c,x 0.2960.01a,c 0.2060.03b 0.2560.02b,c 0.1360.03d 0.2560.02b,c
GFR mL/min 3.3360.36a,e 2.3760.21b 3.1160.22a,b,c 3.7460.46a,c,d 3.2160.27a,b 4.6260.65d 2.4660.28b,e
FENa % 43.664.3a,b 43.062.8a,b 50.463.3a 34.564.2b,d 47.865.4a,c 26.166.5d 53.365.4a
a-Smooth muscle actin
Glomeruli 0.5060.10a 0.3560.08a,c 1.6360.23b 1.4460.15b 0.0860.08c,x 0.5060.00a,c,x 1.3360.11b
Cortical interstitium 0.8260.10a 0.6560.11a 2.6360.23b 1.5660.26c 0.8360.17a 1.2060.12a,c 1.5860.44c
Medullary interstitium 0.9060.10a,c,d,x,y 0.5660.06a 2.3160.28b 1.3660.21c,d,z 0.3060.12a,x 0.7060.20a,c,z 1.5060.52d,y
a–e Groups sharing the same letter are statistically similar (P $ 0.05)
f Except for the groups given quinapril, the body weights, total food intake, and total cholesterol have been previously published and are being reprinted by
permission of Blackwell Science, Inc. from [39] Richards et al: Serum leptin, lipids, free fatty acids, and fat pads in long-term dehydroepiandrosterone-treated Zucker
rats. Proc Soc Exp Biol Med 223:258–262, 2000
x–z Groups sharing the same letter are minimally similar with a strong trend towards a difference at the level of P , 0.07
Table 2. Urine results
Lean Lean Obese Obese Obese Obese DHEA Obese
controls DHEA controls DHEA quinapril and quinapril pair fed
Age 16 weeks
Urine volume mL 14.560.6a,x 11.160.6b 17.660.5c,e,y 17.061.3a,e,x 20.861.3d 16.160.9a,e 14.662.1a,e,y
Proteinuria mg/24 h 21.861.4a 9.760.6a,x 71.3629.6a,b,x 65.9621.2a,b 25.4611.2a,b 96.5667.5b 6.860.6a
Albuminuria mg/24 h 2.360.4a 1.360.2a 16.366.3b,c 19.764.7b,x 4.162.0a,b,c,x 18.9612.8b,c,y 1.160.4a,c,y
Age 20 weeks
Urine volume mL 15.460.7a,x 10.660.7b 18.461.1c,d,y 15.660.9a,d,y 21.161.8c 16.660.9a,d 18.261.4a,c,x
Proteinuria mg/24 h 30.865.9a,c 15.262.4a 187.8661.5b 98.4631.7c 39.5614.5a,c 63.3628.7a,c 33.0620.5a,c
Albuminuria mg/24 h 5.261.7a 2.760.6a,x 61.2621.0b,y 27.167.9a,y 13.766.2a 36.1627.0a,b,x 9.265.3a
Change from week 16 to 20
Delta proteinuria mg/24 h 8.565.6a,c 5.562.7a,c 116.5634.4b 32.5613.6a 14.1615.8a,c 233.2639.3c 26.2620.9a,c
Delta albuminuria mg/24 h 3.061.4a 1.660.7a 44.9616.9b 7.464.2a 10.366.7a 17.2614.3a 4.061.6a
a–e Groups sharing the same letter are statistically similar at the level of P , 0.05
x–y Groups sharing the same letter are minimally similar with a strong trend towards a difference at the level of P , 0.07
increased, compared with lean controls, in all of the Creatinine clearance
obese rats fed ad libitum, with the increase being less in The GFR was determined from the 24-hour urine cre-
the obese rats given DHEA, quinapril, or the combina- atinine clearances. There was no difference in GFR (Ta-
tion. Pair feeding resulted in no additional proteinuria ble 1) between lean and obese controls. The GFR among
above that of the lean controls. The change in proteinuria lean rats was reduced by DHEA administration. The obese
from week 16 to week 20 (delta proteinuria) is also re- rats either pair fed or given DHEA or quinapril alone
ported in Table 2. showed no change in GFR, but administering both DHEA
and quinapril together resulted in an increase in GFR.
Urine albumin excretion
Albuminuria at both 16 and 20 weeks was statistically
Fractional excretion of sodiumsimilar within each phenotype except for the quinapril-
treated and pair-fed groups, which showed less albumin Both lean and obese controls had similar values of
excretion (Fig. 1). However, the change in albuminuria fractional excretion of sodium (FENa; Table 1). DHEA
from week 16 to week 20 (D albuminuria) was reduced by did not alter FENa among lean rats. Obese rats showed
DHEA, quinapril, combination of DHEA plus quinapril, no change in FENa from either quinapril alone or pair
feeding. DHEA reduced FENa in obese rats, and theand pair feeding.
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combination of DHEA and quinapril reduced FENa even stitial fibrosis [19, 44]. This marker is also valid for
activated mesangial cells [19, 20, 23]. DHEA administra-further.
tion slowed the progression of nephropathy in obese
a-Smooth muscle actin Zucker rats compared with obese controls, as evidenced
by the reduction of a-smooth muscle actin staining inThe obese controls, DHEA-treated, and pair-fed groups
had greater glomerular staining of a-smooth muscle actin both cortical and medullary interstitium. However, this
effect was limited to the interstitium, and no benefit wasthan the other groups, while the obese rats treated with
quinapril trended toward the least degree of staining of seen in the glomeruli. Because DHEA leads to reduced
caloric intake, which could be beneficial by itself [45–47],any group (Table 1). The staining of a-smooth muscle
actin in the cortical interstitium was greatest in the obese a separate group of obese rats were fed a calorie-
restricted diet equal to the weekly historical mean caloriccontrols, and treatment with quinapril reduced the extent
of staining to that of the lean controls. The other inter- intake of the DHEA-treated group. These pair-fed, calo-
rie-restricted obese rats also showed reduced staining ofventions, DHEA administration, pair feeding, and the
combination of DHEA plus quinapril, all reduced the a-smooth muscle actin in cortical and medullary intersti-
tium, but not in glomeruli. Since these results are similarextent of cortical interstitial staining to an intermediate
value. The medullary interstitium of the obese controls to that of the DHEA group, they imply that the beneficial
results from DHEA administration on a-smooth muscleexhibited the greatest degree of staining of a-smooth
muscle actin. Either pair feeding or administration of actin staining may be due solely to reduced caloric intake.
Other parameters of renal involvement were also exam-DHEA reduced the medullary staining in obese rats to
levels that were similar to the lean controls. Quinapril ined. Urine albumin excretion at 16 weeks of age was not
significantly changed by DHEA, while calorie restrictiontreatment showed the most important reduction in a-
smooth muscle actin staining. showed a trend toward reduced albuminuria; 20-week
albumin excretion was reduced by calorie restriction and
was nearly reduced by DHEA. Total kidney weight was
DISCUSSION
equally reduced in the obese rats by either DHEA ad-
This study examined the effects of the steroid hormone ministration or calorie restriction, and DHEA lowered
DHEA on the progression of nephropathy in the obese serum creatinine and FENa, while calorie restriction showed
Zucker rat model of type 2 diabetes. DHEA exerts sev- no effect.
eral influences that may be beneficial to the nephropathy The potential effects of DHEA were compared with
of this animal model. Its administration reduces hyper- the benefits from an ACE inhibitor. It is already known
phagia and caloric intake [27, 31–34], causes less weight that ACE inhibitors can slow the progression of diabetic
gain [31–37], and improves their hyperlipidemia [31, 35, nephropathy [48], and they can also limit the tubulointer-
38], all of which should slow the progression of their stitial fibrosis associated with aging [24, 49]. Possible
nephropathy. As expected, the animals given DHEA in mechanisms include hemodynamic effects and reduc-
this experiment ate less food and gained less weight, as tions in some cytokines [50, 51]. Because of the known
reported elsewhere [39]. In addition, also as reported benefits from ACE inhibitors in diabetic nephropathy,
elsewhere, DHEA administration resulted in reduced additional groups of obese rats were treated with either
serum triglycerides and leptin [39]. The effect of DHEA quinapril alone or quinapril in combination with DHEA.
on leptin may be beneficial. Some investigators have As expected, quinapril significantly reduced the degree
shown an effect of leptin on the development of glomeru- of staining of a-smooth muscle actin in the obese rats
losclerosis [40], although the role of leptin is controver- compared with the obese controls. What was not ex-
sial at this time [41]. However, DHEA may also exert pected was the magnitude of this reduction. Quinapril
a beneficial effect on macrophages through modulation reduced the staining of a-smooth muscle actin in cortical
of cytokines because macrophages and cytokines are in- and medullary interstitium to levels comparable to that
volved in the development of nephropathy. DHEA may of the lean controls, while the glomerular staining was
ameliorate some of these adverse effects. For instance, reduced to levels significantly less than that of the lean
DHEA administration lowers serum levels of tumor ne- controls. Quinapril alone or in combination with DHEA
crosis factor-a (TNF-a) and inhibits macrophage produc- had no effect on the already low rates of albumin excre-
tion of TNF-a in a mouse model of endotoxic shock [25]. tion at 16 weeks, but albuminuria at 20 weeks was re-
In this investigation, the degree of nephropathy pres- duced by quinapril alone. Total kidney weight was re-
ent was evaluated by the extent of immunohistochemical duced by both quinapril alone and in combination with
staining of a-smooth muscle actin. Antibodies directed DHEA, but the combination resulted in a greater reduc-
against this cytoskeleton protein [42] will identify a num- tion. Quinapril alone did not alter serum creatinine,
ber of cell types, including smooth muscle cells and myo- GFR, or FENa, but the combination with DHEA lowered
creatinine and FENa and raised GFR.fibroblasts [43], and have been used as markers of inter-
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